Soleno Therapeutics, a Neurocrine Biosciences company, develops therapies for rare genetic disorders. The first and only therapy for the treatment of hyperphagia in #PraderWilliSyndrome received full FDA-approval in March 2025.
C-US-PWS-00066
Shared 1 year ago
5.8K views
Shared 1 year ago
225 views
Shared 1 year ago
88 views
Shared 1 year ago
157 views
Shared 1 year ago
4K views
Shared 1 year ago
430 views
Shared 2 years ago
300 views
Shared 2 years ago
843 views
Shared 2 years ago
282 views